Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
NCT03054532Phase 2Unknown
- Sponsor
- Singapore General Hospital
- Start
- Jul 2017
- Primary completion
- Jan 2021
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and lenalidomide in Natural killer T-cell lymphoma (NKTL), sponsored by Singapore General Hospital. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
durvalumablenalidomide
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT03054532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054532.